Bifidobacterium catenulatum

Bacteria
General | Carbohydrate O/F | Substrate utilisation | Enzymes | Metabolites | Antibiotics

Overview

  • Bifidobacterium catenulatum is a Gram-positive, non-spore-forming, anaerobic, non-motile, rod-shaped bacterium. It has been detected in at least 17 gut microbiome compilation studies or metastudies. The DNA G+C content is 54.7%. Bifidobacterium catenulatum is a common gut coloniser. (Morita2011; Scardovi1974)



  • This organism has been recovered from human faeces. The risk classification (www.baua.de) for this organism is 1, i.e., low risk of infection and spread. Pathogenicity status unknown, or very unlikely to be pathogenic. Is a known gut commensal.
    • GENERAL CHARACTERISTICS (Morita2011); (Scardovi1974);
    Character Response
  • Substrates hydrolysed or digested:
  • aesculin;
  • ±
  • Strain-dependent hydrolysis or digestion:
  • milk;
  • pH
  • Acidity tolerance:
  • Grows optimally at pH 6.5-6.9.
  • 🌡
  • Temperature tolerance:
  • grows at 28℃; grows at 43℃; Grows optimally at 39-41℃.
  • H+
  • Acid from carbohydrates usually produced:
  • galactose; glucose; ribose; xylose; amygdalin; cellubiose; lactose; maltose; raffinose; sucrose; sorbitol; salicin;
  • ±
  • Strain-dependent acid from carbs:
  • starch; 5-ketogluconate;
  • ⥅
  • Substrates assimilated or utilised:
  • melibiose;
  • Active enzymes:
  • Ala arylamidase; Ala-Phe-Pro arylamidase; acid phosphatase; esterase C4; esterase lipase C8; α-galactosidase; β-galactosidase; α-glucosidase; β-glucosidase; Gly arylamidase; Leu arylamidase; Leu-Gly arylamidase;
    • SPECIAL FEATURES (Morita2011); (Scardovi1974);
    Character Response
  • ✓
  • Metabolites produced:
  • acetate (major); lactate;
  • ✗
  • Metabolites not produced:
  • indole;
  • ✗
  • VP test:
  • not active
  • ✗
  • Nitrate:
  • not reduced
    • RESPONSE TO ANTIBIOTICS (Goldstein2003); (Matteuzzi1983); (Goldstein2013); (Goldstein2013a); (Citron2003);
    Class Active Resistant
  • Penicillins:
  • amoxicillin; amoxicillin-clavulanic acid; ampicillin; cloxacillin; imipenem; oxacillin; penicillin G; piperacillin; piperacillin-tazobactam; ticarcillin;
  • Cephalosporins:
  • cefotaxime; cefotetan; cefoxitin; cephalothin;
  • Macrolides:
  • erythromycin; fidaxomicin; pristinamycin; quinupristin-dalfopristin; spiramycin; telithromycin;
  • Tetracyclines:
  • minocycline; tetracycline;
  • Quinolines:
  • ciprofloxacin; gatifloxacin;
  • nalidixic-acid;
  • Aminoglycosides:
  • gentamicin; kanamycin; neomycin; streptomycin;
  • Polypep/ketides:
  • bacitracin; nisin A; rifampicin;
  • Heterocycles:
  • chloramphenicol; nitrofurantoin;
  • metronidazole;
  • Vancomycins:
  • vancomycin; teicoplanin;
  • Miscellaneous antibiotics:
  • clindamycin; daptomycin; lincomycin; linezolid; pristinamycin; telithromycin;
  • polymyxin B;

  • Scardovi, V., & Crociani, F. (1974). Bifidobacterium catenulatum, Bifidobacterium dentium, and Bifidobacterium angulatum: Three New Species and Their Deoxyribonucleic Acid Homology Relationships. International Journal of Systematic Bacteriology, 24(2), 310–310.

    • Details

    GENERAL
    Lineage Physiology General Growth Tolerances Hydrol./digest./degr.
    Phylum:  Actinobacteria Class:  Actinomycetia Order:  Bifidobacteriales Family:  Bifidobacteriaceae Genus:  Bifidobacterium Gram stain:  + O2 Relation.:  anaerobic Spore:  No spore Motility:  Sessile Morphology:  Rod
    Health:  Unknown
    Source:  human faeces
    DNA G+C(%):  54.7
    Opt. T:  39-41℃
    Lower T(℃):  28(+)
    High T(℃):  43(+)
    Opt. pH:  6.5-6.9
    		Aesculin:  + Urea:  neg Gelatin:  neg Hippurate:  neg Milk:  curdle
    CARBOHYDRATE ACID FORMATION
    Monosaccharide O/F Oligosaccharide O/F Polysaccharide O/F Polyol O/F Other O/F
    D-Arabinose:  neg Fructose:  vr Fucose:  neg D-Fucose:  neg Galactose:  + Glucose:  + Mannose:  neg D-Lyxose:  neg Rhamnose:  neg Ribose:  + Sorbose:  neg D-Tagatose:  neg Xylose:  + L-Xylose:  neg Cellubiose:  + Gentiobiose:  vr Lactose:  + Maltose:  + Melezitose:  neg Sucrose:  + Trehalose:  vr Turanose:  vr Amygdalin:  + Dextrin:  neg Glycogen:  neg Inulin:  neg Starch:  d Adonitol:  neg D-Arabitol:  neg L-Arabitol:  neg Dulcitol:  neg Erythritol:  neg Glycerol:  neg Inositol:  neg Mannitol:  neg Sorbitol:  + Xylitol:  neg Arbutin:  vr Gluconate:  vr 2-Ketogluconate:  neg 5-Ketogluconate:  d Me-α-D-Glc:  vr Me-α-D-Mann:  neg Me-Xyloside:  neg NAc-α-GA:  neg Salicin:  +
    SUBSTRATE ASSIMILATION & UTILISATION
    Monosaccharide util/assim Oligosaccharide util/assim Other carboh. util/assim Amino acid util/assim Organic acid util/assim
    Melibiose:  +
    ENZYME ACTIVITY
    Enzymes: General Enzymes: Carbohydrate Enzymes: Protein Enzymes: Arylamidases Enzymes: Esters/fats
    Oxidase:  neg Catalase:  neg Urease:  neg Ac-β-glcamnd:  neg α-Fucosidase:  vr α-Galactosidase:  + β-Galactosidase:  + α-Glucosidase:  + β-Glucosidase:  + β-Glucuronidase:  neg α-Mannosidase:  neg β-Mannosidase:  neg ArgDH:  neg GluDC:  neg AlanineAA:  + AlaPheProAA:  + GluGluAA:  neg GlyAA:  + LeuAA:  + LeuGlyAA:  + PyrrolidAA:  neg AlkalineP:  neg AcidP:  + Esterase(C4):  + EstLip(C8):  + Lipase(C14):  neg
    METABOLITES - PRODUCTION & USE
    Fuel Usable Metabolites Metabolites Released Special Products Compounds Produced

    		Acetate:  Major(+) Lactate:  + Indole:  neg
    ANTIBIOTICS ℞
    Penicillins & Penems (μg/mL) Cephalosporins (μg/mL) Aminoglycosides (μg/mL) Macrolides (μg/mL) Quinolones (μg/mL)
    amoxicillin:  Sens
    Augmentin:  Sens
    ampicillin:  S(MIC50): 0.125, MIC90: 0.5, RNG: (0.03–1)
    cloxacillin:  Sens
    oxacillin:  Sens
    penicillin_G:  S(MIC50): 0.125, MIC90: 0.5, RNG: (≤0.03-0.5)
    piperacillin:  Sens
    piper-taz:  S(MIC50): 0.06, MIC90: 0.5, RNG: (≤0.03-1)
    ticarcillin:  Sens
    imipenem:  S(MIC50): 0.06, MIC90: 0.5, RNG: (0.015–2)
    cefotaxime:  Sens
    cefotetan:  Sens
    cefoxitin:  S(MIC50): 2, MIC90: 8, RNG: (0.5–32)
    cephalothin:  Sens
    gentamicin:  Res
    kanamycin:  R(>300)
    neomycin:  R(100-400)
    streptomycin:  R(100->1500)
    erythromycin:  S(MIC50): 0.23, MIC90: 0.35, RNG: (0.1-0.5)
    fidaxomicin:  S(MIC50): 0.125, MIC90: 0.125, RNG: (0.03–0.25)
    pristinamycin:  Sens
    quin-dalf:  S(MIC50): 0.25, MIC90: 0.25, RNG: (0.125-0.5)
    spiramycin:  Sens
    telithromycin:  Sens
    linezolid:  S(MIC50): 1, MIC90: 1, RNG: (0.25–2)
    ciprofloxacin:  Sens
    gatifloxacin:  Sens
    moxifloxacin:  Var(MIC50): 1, MIC90: 8, RNG: (0.06–16)
    nalidixic-acid:  R(>200)
    Tetracyclines (μg/mL) Vancomycin Class (μg/mL) Polypep/ketides (μg/mL) Heterocycles (μg/mL) Other (μg/mL)
    minocycline:  Sens
    tetracycline:  S(MIC50): <3, MIC90: 4.5, RNG: (3-5)
    teicoplanin:  S(MIC50): 0.25, MIC90: 0.5, RNG: (0.125–0.5)
    vancomycin:  S(MIC50): 0.5, MIC90: 1, RNG: (0.25-1)
    bacitracin:  S(MIC50): 0.1, MIC90: 0.21, RNG: (0.05-0.40)
    nisin_A:  Sens
    rifampicin:  Sens
    chloramphenicol:  S(MIC50): 2.8, MIC90: 3.7, RNG: (2-4)
    metronidazole:  R(MIC50): 32, MIC90: >32, RNG: (0.125->32)
    nitrofurantoin:  S(MIC50): <15, MIC90: 13, RNG: (15-20)
    clindamycin:  S(MIC50): 0.03, MIC90: 0.03, RNG: (0.03–0.25)
    lincomycin:  Sens
    daptomycin:  S(MIC50): 0.25, MIC90: 0.5, RNG: (≤0.03-1)
    polymyxin_B:  R(>700)

    References

    SPECIFIC REFERENCES FOR BIFIDOBACTERIUM CATENULATUM
  • Goldstein2003 - In Vitro Activities of Daptomycin, Vancomycin, Quinupristin- Dalfopristin, Linezolid, and Five Other Antimicrobials against 307 Gram-Positive Anaerobic and 31 Corynebacterium Clinical Isolates.
  • Matteuzzi1983 - Antimicrobial susceptibility of Bifidobacterium.
  • Morita2011 - Bifidobacterium kashiwanohense sp. nov., isolated from healthy infant faeces.
  • Scardovi1974 - Bifidobacterium catenulatum, Bifidobacterium dentium, and Bifidobacterium angulatum: Three New Species and Their Deoxyribonucleic Acid Homology Relationships.
  • DeAngelis2013 - Fecal microbiota and metabolome of children with autism and pervasive developmental disorder not otherwise specified
  • ElMouzan2018 - Microbiota profile in new-onset pediatric Crohn's disease: data from a non-Western population
  • Gryp2020 - Isolation and Quantification of Uremic Toxin Precursor-Generating Gut Bacteria in Chronic Kidney Disease Patients
  • Kerckhoffs2009 - Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients
  • Malinen2005 - Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR
  • Miragoli2017 - Impact of cystic fibrosis disease on archaea and bacteria composition of gut microbiota
  • Tarallo2019 - Altered Fecal Small RNA Profiles in Colorectal Cancer Reflect Gut Microbiome Composition in Stool Samples
  • Xu2012 - Changes of fecal Bifidobacterium species in adult patients with hepatitis B virus-induced chronic liver disease
  • Goldstein2013 - In vitro activity of Biapenem plus RPX7009, a carbapenem combined with a serine β-lactamase inhibitor, against anaerobic bacteria.
  • Goldstein2013a - Comparative in vitro activities of SMT19969, a new antimicrobial agent, against Clostridium difficile and 350 gram-positive and gram-negative aerobic and anaerobic intestinal flora isolates.
  • Citron2003 - In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria.
  • ...............................
    • GUT MICROBIOME COMPILATIONS AND METASTUDIES FOR BIFIDOBACTERIUM CATENULATUM
  • Byrd2020 - Stability and dynamics of the human gut microbiome and its association with systemic immune traits.
  • Chen2020 - Structural and Functional Characterization of the Gut Microbiota in Elderly Women With Migraine
  • Chen2020a - Featured Gut Microbiomes Associated With the Progression of Chronic Hepatitis B Disease
  • Chung2019 - Impact of carbohydrate substrate complexity on the diversity of the human colonic microbiota.
  • Dubinkina2017 - Links of gut microbiota composition with alcohol dependence syndrome and alcoholic liver disease
  • Forster2019 - A human gut bacterial genome and culture collection for improved metagenomic analyses.
  • Hu2019 - The Gut Microbiome Signatures Discriminate Healthy From Pulmonary Tuberculosis Patients
  • Jie2017 - The gut microbiome in atherosclerotic cardiovascular disease
  • Karlsson2013 - Gut metagenome in European women with normal, impaired and diabetic glucose control
  • Lagier2016 - Culture of previously uncultured members of the human gut microbiota by culturomics.
  • New2022 - Collective effects of human genomic variation on microbiome function.
  • RajilicStojanovic2014 - The first 1000 cultured species of the human gastrointestinal microbiota.
  • Rothschild2018 - Environment dominates over host genetics in shaping human gut microbiota.
  • Tyakht2013 - Human gut microbiota community structures in urban and rural populations in Russia.
  • Wang2018 - A metagenome-wide association study of gut microbiota in asthma in UK adults
  • Wang2018a - Morphine induces changes in the gut microbiome and metabolome in a morphine dependence model.
  • Woodmansey2004 - Comparison of compositions and metabolic activities of fecal microbiotas in young adults and in antibiotic-treated and non-antibiotic-treated elderly subjects.
  • Zeller2014 - Potential of fecal microbiota for early-stage detection of colorectal cancer
  • ...............................
    • GENERAL REFERENCES FOR BIFIDOBACTERIUM CATENULATUM
  • CCUG - Culture Collection University of Gothenburg - Entire Collection
    • Added: April 08, 2021